Tech Bounces Back, Tango Hits All-Time High, and Oil Jumps on Iran-Israel

Friday’s selloff was rough. Monday was better.

Chip stocks recovered, Tango Therapeutics hit an all-time high on what may be the most significant oncology data of the year, and Apple kicked off its Worldwide Developers Conference with a rebuilt Siri.

Oil jumped on new Iran-Israel exchanges. SpaceX is listing this week. Today’s edition has everything.

Capital gains taxes may quietly reduce more of your investment returns than you realize.

But the tax code includes several strategies that may help reduce that bill.

Three often-overlooked areas include investment-related expenses, cost basis adjustments, and real estate selling costs.

When structured correctly, these deductions may help minimize taxable gains.

Because the rules can be complex, many investors work with fiduciary financial advisors to plan tax-efficient strategies.

Use SmartAsset’s free tool to find vetted financial advisors serving your area.

The CEO of a $30 billion genetic testing stock just sold roughly $9.1 million after a strong one-year run, while a director at a beaten-down alternative asset manager bought more than $1.1 million near the stock’s 52-week low. You’re seeing two very different insider signals. Insider readers are seeing where leadership is cashing in on strength — and where one director is buying weakness with real conviction.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Tech stocks staged a partial recovery from Friday’s selloff as Nvidia CEO Jensen Huang told Computex that AI will create more software jobs rather than eliminating them, dispelling what the market had dubbed “SaaSpocalypse” fears.

Oil jumped after Iran and Israel exchanged strikes overnight, with Brent briefly reaching $98 before pulling back below $100, adding another chapter to the Strait of Hormuz saga.

Apple kicked off its Worldwide Developers Conference with the unveiling of a rebuilt Siri powered by Google’s Gemini technology, the iPhone maker’s third attempt to stake a claim in AI.

Marvell Technology jumped after being named for S&P 500 inclusion, while SpaceX is expected to begin trading later this week in what analysts expect will be the largest IPO on record.

Johnson & Johnson (NYSE: JNJ) is making a major move in oncology by acquiring Firefly Bio for $1 billion in cash.

The deal gives J&J access to a cancer drug platform designed to send treatment directly into tumor cells, strengthening its push into targeted medicines for some of the hardest cancers to treat.

For J&J, the business angle is clear.

The company is not only adding another biotech asset but also expanding its ability to develop cancer treatments that are more precise, more selective, and potentially more powerful than older approaches.

Hard Tumors Are the Prize

Firefly Bio’s work focuses on cancers associated with KRAS, a target that has been difficult for drugmakers to target.

That matters because patients in this area still have limited options, giving J&J a chance to push into a field where better treatments are badly needed.

That makes your company read stronger.

J&J is not chasing an easy add-on; it is going after a tougher cancer category where a real breakthrough would carry serious medical and commercial weight.

Pipeline Depth Matters Now

Big pharma companies need constant renewal as older drugs face competition, and future growth depends on stronger pipelines.

Deals like this help J&J add new science, new assets, and new ways to compete in specialty medicine.

The company is clearly building toward a future in which cancer drugs play a larger role in its identity.

If Firefly Bio’s platform delivers, you get J&J moving further into the high-value oncology race with a tool aimed at tumors that have frustrated drugmakers for years.

Accenture (NYSE: ACN) is making a major move by agreeing to acquire Whalar, a creator and social agency that will become part of Accenture Song.

The deal gives Accenture stronger creator, influencer, and social commerce capabilities at a time when brands are being discovered through creators as much as traditional ads.

For Accenture, the importance is clear.

The company is not just selling consulting advice; it is building a larger growth engine for clients that need to win attention, trust, and sales in a social-first world.

Creators Become Boardroom Business

Creator marketing is no longer a side experiment for brands. It has become a serious channel where companies launch products, shape culture, and influence buying decisions.

The company is moving closer to the actual places where consumer attention now lives.

That makes your read on Accenture sharper. The company is building beyond traditional marketing services and moving deeper into the engine that drives modern brand relevance.

Social Becomes the Growth Lane

Brands want campaigns that feel real, move quickly, and connect with audiences across platforms. Accenture is positioning itself to deliver that at enterprise scale, not just through one-off influencer posts.

The company is carving out a larger role in how brands grow online.

If this integration works, you get Accenture becoming a stronger force in the creator economy, where culture, commerce, and customer growth now meet.

His reported salary? $400,000 annually.

Yet the bigger number tells a different story:

Up to $250,000 each month… from one channel.

It’s not property. It’s not stocks.

So what’s behind this kind of consistent income — and why is it catching attention right now?

See how you can begin with under $20.

Lockheed Martin (NYSE: LMT) is facing a fresh business challenge around its flagship F-35 program after Denmark's official audit found that long-term costs for its fighter jet purchase are far higher than earlier government estimates.

Denmark is not the main story here.

The company's story is that Lockheed's biggest defense franchise is entering a period in which customers are not only asking whether they need the aircraft but also whether they can manage the full cost of owning it.

A Flagship Program Faces Cost Scrutiny

The F-35 remains central to modern defense planning, especially as NATO countries increase military spending.

Lockheed still has a product that many governments want, but rising long-term cost concerns can make future approvals harder and more political.

Lockheed is not fighting demand; it is fighting the pressure that comes when customers must explain the full ownership cost to taxpayers and lawmakers.

Lockheed's Next Test Is Execution

The company's future F-35 momentum depends on maintaining customer confidence in delivery schedules, operating costs, service support, and upgrades.

That is where trust becomes part of the product.

If Lockheed handles this well, you get a company protecting one of the most important defense platforms in the world.

If cost concerns spread, the F-35 stays essential, but the sales conversation becomes much harder.

Optical Cable [OCC] $19.00 (+54.47%)

Optical Cable makes fiber optic cables for data centers and defense networks, and ran on Nvidia's AI factory reference architecture, naming fiber optic interconnects as core hyperscale infrastructure.

At a $176M Strong Buy-rated market cap with 35x relative volume, the move confirms fiber optic infrastructure is a genuine AI supply chain beneficiary.

Tango Therapeutics [TNGX] $30.93 (+52.97%)

Vopimetostat combined with daraxonrasib hit a 92% objective response rate in pancreatic cancer patients, with 100% disease control and 90% progression-free at six months.

Wolfe Research called it groundbreaking and raised peak sales to $2.6B. Pancreatic cancer is one of the hardest cancers to treat, and this data made researchers stop what they're doing.

Motorcar Parts [MPAA] $14.25 (+34.56%)

Motorcar Parts beat Q4 estimates on EPS and revenue and raised full-year guidance.

The Iran war's sustained high gas prices are a structural tailwind here: consumers keeping older vehicles longer drives demand for remanufactured alternators, starters, and wheel hubs.

Sometimes the war trade works in unexpected directions.

TOYO [TOYO] $13.18 (-16.31%)

TOYO makes high-precision electronic components and had been running on the chip sector momentum.

The AI rebound proved uneven, with capital flowing back into the biggest names rather than smaller component suppliers.

The $480M Strong Buy-rated company gave back recent gains with no specific negative catalyst behind the move.

Wealthfront [WLTH] $8.41 (-14.62%)

Q1 revenue of $90.5M missed the $93.4M estimate, and EPS of $0.07 missed $0.12 by a wide margin, even as assets hit record levels.

Growing assets but missing revenue is a confusing story, and the $1.23B Buy-rated robo-advisor is paying the premium-compression price for it.

Brady Corporation [BRC] $75.24 (-15.05%)

Brady reported Q3 earnings that beat EPS but disappointed on revenue, citing softer industrial demand and higher energy costs.

The $3.51B Buy-rated company's full-year guidance came in at the low end of prior estimates, removing the upside thesis that had been supporting the premium multiple.

For a moment…

Forget about Trump’s ties to Israel.

Forget about reports of Iran’s nuclear program.

Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.

Click here to find out what it is.

If you have even a single dollar invested in the U.S. stock market, this is going to directly impact you.

Discover the reason here.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.